GenMark Diagnostics, Inc. (NASDAQ:GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that their eSensor® Warfarin Sensitivity Test has been selected for use in a new pivotal Warfarin clinical study; the WARFARIN Trial (Warfarin Adverse event Reduction For Adults Receiving genetic testing at therapy INitiation). The trial will seek to evaluate the value of genetic testing on reducing adverse events associated with Warfarin therapy.
“We selected GenMark Diagnostics' technology for its ability to provide accurate and reliable results. The XT-8 allows fast processing and simple interpretation of patient results”
Eligible patients in this clinical study will be reimbursed by the Centers for Medicare and Medicaid Services (CMS) through a temporary code developed to enable the implementation of pharmacogenomic testing under the Coverage with Evidence Development (CED) provision in the Social Security Act. GenMark's selection for use in the WARFARIN trial was made by Iverson Genetics. "We selected GenMark Diagnostics' technology for its ability to provide accurate and reliable results. The XT-8 allows fast processing and simple interpretation of patient results," stated Dean Sproles, CEO of Iverson Genetics.
"We are pleased to have our leading Warfarin Sensitivity Test selected for inclusion in this clinical study," said Christopher Gleeson, CEO of GenMark Diagnostics. "We believe that the ease of use of our eSensor XT-8 system provides a clear choice for diagnostic laboratories and research centers."
New machine learning model achieves breakthrough in heart disease prediction with over 95% accuracy